Citations

Clear

9383 citation(s) found for "Thomas, PS".

Petechial hemorrhage in mechanical thrombectomy for distal and medium-vessel occlusions: technical considerations and outcomes
Baker, Amanda , Adeeb, Nimer , Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Cancelliere, Nicole M., Fiehler, Jens, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Yedavalli, Vivek , Stracke, Christian Paul , Shaikh, Hamza, Liebeskind, David S., Alexandre, Andrea , Faizy, Tobias D., Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Altschul, David , _, _, Amllay, Abdelaziz, Gopinathan, Anil, Dusart, Anne , Capirossi, Carolina , Mounayer, Charbel, Hsieh, Cheng-Yang, Stapleton, Christopher J. , Bellante, Flavio, Shaikh, Hamza , Cuellar-Saenz, Hugo H., Rabinov, James D. , Berge, Jérôme , Martinez-Gutierrez, Juan Carlos, Premat, Kévin , Chervak, Lina , Elhorany, Mahmoud, Quintero‐Consuegra, Miguel , Kan, Peter , Khandelwal, Priyank , Kadirvel, Ramanathan , Dofuku, Shogo , Nedelcu, Simona, Tjoumakaris, Stavropoula I, Barreau, Xavier, Liebeskind, David S. , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Gonzalez, Nestor R , Regenhardt, Robert W , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Essibayi, Muhammed Amir , Salim, Hamza , Fazzari, Melissa J. , Khatri, Deepak , Baker, Amanda, Musmar, Basel , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Aziz, Yasmin , Radu, Răzvan Alexandru , Klein, Piers , Ota, Takahiro , Mowla, Ashkan , Naamani, Kareem El , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Hecker, Constantin , Marnat, Gaultier , Griessenauer, Christoph J. , Pedicelli, Alessandro , Faizy, Tobias D. , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Amllay, Abdelaziz , Vagal, Achala , Schiphorst, Adrien ter , Thomas, Ajith J , Mounayer, Charbel , Weyland, Charlotte S. , Hsieh, Cheng‐Yang , Forestier, Géraud , Cuellar, Hugo , Valente, Iacopo , Sibon, Igor , Jesser, Jessica , Martinez-Gutierrez, Juan Carlos , Meyer, Lukas , Elhorany, Mahmoud , Aziz‐Sultan, Mohammad Ali , Killer-Oberpfalzer, Monika , Khandelwal, Priyank , Fahed, Robert , Salazar‐Marioni, Sergio , Nedelcu, Simona , Tjoumakaris, Stavropoula , Saleme, Suzana , Barreau, Xavier

Mayo Clinic

Journal of Neurosurgery | July 4, 2025 | Volume: 143 | Issue: 6 | Pages: 1501-1513

10.3171/2025.3.jns243030 | PMID 40614268 Get It

OBJECTIVE Mechanical thrombectomy (MT) is well established for large-vessel occlusion (LVO) strokes, but its safety in distal and medium-vessel occlusions (DMVOs) requires further investigation. This study analyzed the relationship between procedural approaches, petechial hemorrhage (PetH), and clinical outcomes in DMVO thrombectomy, with particular attention to technical considerations and the complex interplay between tissue injury and hemorrhagic complications. METHODS A retrospective cohort study was conducted on DMVO stroke patients treated with MT at 37 stroke centers worldwide from 2016 to 2024. Patients were categorized based on follow-up imaging into those with or without PetH. Four logistic regression models analyzed the association of PetH with favorable functional outcomes (modified Rankin Scale score ≤ 2) at 90 days, early neurological improvement (≥ 4-point National Institutes of Health Stroke Scale score decrease at 24 hours), all-cause mortality, and independent determinants of PetH. Adjusted odds ratios (aORs), 95% confidence intervals, and p values were reported. RESULTS Of 1428 patients, 439 (30.7%) developed PetH. Factors independently associated with PetH were multiple thrombectomy passes (aOR 1.58, 95% CI 1.21–2.06; p = 0.001), IV thrombolysis (aOR 1.31, 95% CI 1.01–1.69; p = 0.04), and the combined use of a stent retriever with aspiration as the first-line method compared with aspiration alone (aOR 1.66, 95% CI 1.15–2.38; p = 0.007). Conversely, general anesthesia (aOR 0.55, 95% CI 0.40–0.77; p < 0.001), higher Alberta Stroke Program Early CT Scores (aOR 0.76, 95% CI 0.69–0.83; p < 0.001), and successful recanalization (aOR 0.56, 95% CI 0.39–0.80; p = 0.002) were significantly associated with a lower odds of PetH. PetH was associated with a decreased odds of favorable functional outcomes (aOR 0.51, 95% CI 0.36–0.73; p < 0.001), reduced early neurological improvement (aOR 0.59, 95% CI 0.44–0.79; p < 0.001), and increased all-cause mortality (aOR 1.84, 95% CI 1.23–2.76; p < 0.001). CONCLUSIONS PetH is a frequent sequela following MT in DMVO strokes and is associated with poorer outcomes, likely reflecting underlying ischemic injury rather than direct causation. Procedural factors influence PetH risk, suggesting medical treatment as first-line therapy for DMVOs, with MT reserved for refractory cases using less aggressive approaches.
Discovery of an autoinhibited conformation in mesotrypsin reveals a strategy for selective serine protease inhibition
Coban, Matt , Gokara, Mahesh , Tanzer, Sarah D., Zhou, Sherry X. , Hockla, Alexandra , Sankaran, Banumathi , Caulfield, Thomas R. , Radisky, Evette S. , Forero Vargas, Luis M, Zhou, Sherry X , Hockla, Alexandra , Sankaran, Banumathi , Caulfield, Thomas R , Radisky, Evette S , Coban, Mathew A , Vargas, Luis M. Forero

Mayo Clinic

Science Advances | July 4, 2025 | Volume: 11 | Issue: 27 | Pages: No page available

10.1126/sciadv.adu9129 | PMID 40614191 Get It

Selective inhibition of the more than 100 S1 family serine proteases is a long-standing challenge due to their active site similarity. Mesotrypsin, implicated in cancer progression, exemplifies these difficulties; no current inhibitors achieve selectivity over other human trypsins. We found an unexpected autoinhibited conformation of mesotrypsin via x-ray crystallography, revealing a cryptic pocket adjacent to the active site. Using high-throughput virtual screening targeting this cryptic pocket, we identified a conformationally selective small-molecule inhibitor that stabilizes the inactive state of mesotrypsin. This inhibitor demonstrates selectivity for mesotrypsin over other trypsins. Our findings challenge the accepted view of digestive trypsins as constitutively active enzymes lacking potential for allosteric regulation. Furthermore, analyses of other structures suggest that dynamic sampling of closed states with analogous allosteric cryptic pockets appears widespread among S1 serine proteases. These observations point to a potentially generalizable strategy to achieve selective inhibition, offering broad implications for drug development targeting serine proteases in cancer and other diseases.
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma
Abeykoon, Jithma P. , Zhu, Guangli, Hirohashi, Yuna, Moreau, Lisa A. , Mukkavalli, Sirisha , Parmar, Kalindi , Zambrano, Gabriella, Jiang, Lige, Gwin, Kimberly, King, Rebecca L. , Wu, Xiaosheng , Yi, Dongni , Asada, Shuhei , Zhu, Guangli, Iyer, Divya , Zambrano, Gabriella, Manske, Michelle K. , Cerhan, James R. , Lou, Zhenkun , Shapiro, Geoffrey I. , Witzig, Thomas E. , D’Andrea, Alan D.

Mayo Clinic

Journal of Clinical Investigation | July 3, 2025 | Volume: 135 | Issue: 17 | Pages: No page available

10.1172/jci193006 | PMID 40608419 Get It

Oncogene expression can cause replication stress (RS), leading to DNA double-strand breaks (DSBs) that require repair through pathways such as homologous recombination, nonhomologous end-joining, and microhomology-mediated end-joining (MMEJ). Cyclin D1 (encoded by CCND1 ) is a well-known oncoprotein overexpressed in cancer; however, its role in RS is unknown. Using mantle cell lymphoma (MCL) as a naturally occurring model of cyclin D1 overexpression, we examined the impact of cyclin D1 on RS and DSB repair mechanisms. Cyclin D1 overexpression elevated RS, increased DNA damage, especially during mitosis, and caused specific upregulation of MMEJ. Furthermore, cyclin D1 activated polymerase theta ( POLQ ) transcription by binding its promoter loci, driving POLΘ-mediated MMEJ that is essential to withstand cyclin D1–induced RS. Moreover, concurrent ATM deficiency further intensified RS, enhanced POLQ expression, and heightened reliance on MMEJ-mediated DNA damage repair. Consequently, inhibition of POLΘ in cyclin D1–overexpressed settings further exacerbated RS, causing single-strand DNA gap accumulations and chromosomal instability, ultimately leading to apoptosis, an effect amplified in ATM-deficient cells. Targeting MMEJ via POLΘ inhibition is therefore an effective strategy in the context of cyclin D1 overexpression and ATM deficiency and may provide a unique therapeutic approach for treating MCL and other malignancies characterized by similar alterations.
Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure—A multivariable model with APRI+ALBI
Dong, Yawen , Gregory, Lindsey A., Podrascanin, V. , Ammann, M. , Hackl, Hubert , Li, Zhihao , Starlinger, Johannes, Truty, Mark J. , Warner, Susanne G, Smoot, Rory L. , Nagorney, David M. , Podrascanin, Vanja , Santol, Jonas , Ammann, Markus , Pereyra, David , Hackl, Hubert , Li, Zhihao , Warner, Susanne G , Gruenberger, Thomas , Nagorney, David M , Starlinger, Patrick , Smoot, Rory L , Truty, Mark J , Dong, Yawen , Santol, Jonas , Pereyra, David , Starlinger, Johannes, Warner, Susanne G.

Mayo Clinic

Liver Transplantation | July 3, 2025 | Volume: 31 | Issue: 12 | Pages: 1450-1463

10.1097/lvt.0000000000000676 | PMID 40607909 Get It

Portal hypertension is a key factor in posthepatectomy liver failure (PHLF). While preoperative liver function tests like APRI+ALBI assess liver function, they only partially reflect portal hypertension severity. Elevated von Willebrand factor antigen (vWF-Ag) indicates endothelial dysregulation and correlates with portal hypertension. Combining vWF-Ag with APRI+ALBI may enhance PHLF prediction. A total of 534 patients who underwent liver resection at Mayo Clinic Rochester (2020–2024) were analyzed for PHLF incidence, postoperative morbidity, and 90-day mortality. Predictive probability for PHLF was assessed using receiver operating characteristic analysis and validated in an external Austrian cohort of 283 patients (2008–2017). vWF-Ag was then integrated into the existing APRI+ALBI multivariable model. PHLF grade B/C was reported in 56 patients (10.5%). The 90-day mortality rate was 0.9% (n=5). Using 2 cutoffs (182%, 240%), vWF-Ag was found to be an independent predictive factor for PHLF grade B/C that remained statistically significant upon multivariable analysis. The combination of preoperative APRI+ALBI and vWF-Ag increased the positive predictive value to 27.9% for PHLF grade B/C in the APRI+ALBI high and vWF-Ag high group. Incorporation of vWF-Ag into the established APRI+ALBI-based multivariable model revealed a superior AUC of 0.772 for PHLF risk stratification and was successfully validated in an independent cohort (AUC=0.834). The combination of vWF-Ag with APRI+ALBI demonstrates a favorable predictive potential for PHLF risk assessment. We provide 2 pathways for clinical assessment: (1) a cutoff-based system and (2) a more complex multivariable model that can be calculated in a specifically designed smartphone application.
The Minnesota Conference proposed guidelines for education and training in clinical neuropsychology
Stringer, Anthony Y. , Fuchs, Kathleen , Edgar, Veronica Bordes , Correia, Stephen , Penna, Suzanne , Whiteside, Douglas M. , Bodin, Douglas, Butt, Sakina M. , Dodzik, Peter , Fernandes, Mary A. , Freece, Krista, Fuller, Richard, Getz, Glen E., Harder, Lana , Irani, Farzin , Janzen, Laura , Kaseda, Erin T. , Kramer, Megan , Kubu, Cynthia S. , Lafosse, Jose M., Lee-DaRocha, Jennifer, MacDonald, Beatriz , Strutt, Adriana M. , McBride, W.E., Mucci, Grace , Nayar, Kritika , Paltzer, June Yu, Ray, Courtney , Ready, Rebecca E. , Schmitt, Taylor Rose , Rush, Beth , Stanford, Lisa D., Patten, Ryan Van , Verroulx, Kris, Wilson, Jaime, Wright, Ingram , Zartman, Andrea L., Fujii, Daryl , Heffelfinger, Amy , Rey‐Casserly, Celiane , Whiteside, Douglas , Block, Cady, Calamia, Matthew , M Dotson, Vonetta , Johnstone, Brick , Kaseda, Erin , Madore, Michelle , Medina, Luis Daniel , Sperling, Scott , Stiers, William , Stricker, Nikki H , Bilder, Robert , Heffelfinger, Amy , Schmitter-Edgecombe, Maureen , Bristow, Thomas, Reyes, Anny , Block, Cady K. , Calamia, Matthew , Didehbani, Nyaz , Fuller, Richard, Harder, Lana, McBride, Will, Medina, Luis D. , Singh, Shifali M. , Sperling, Scott A. , Stricker, Nikki H. , Thornton, Allen E. , Vandermorris, Susan , Parsons, Thomas D. , Puente, Antonio E. , Roper, Brad L.

Mayo Clinic

The Clinical Neuropsychologist | July 2, 2025 | Volume: 40 | Issue: 2 | Pages: 331-375

10.1080/13854046.2025.2520957 | PMID 40604361 Get It

Practice advisory for intravenous management of headache disorders in hospitalized patients: a review of the evidence and consensus recommendations
Hoydonckx, Yasmine , Feoktistov, Alexander, Amoozegar, Farnaz , Anderson, C. , Barad, Meredith , Burke, Emeralda , Chitsantikul, Prin, Doshi, Tina L , Englesakis, Marina , Goel, Akash , Gupta, Himanshu , Kirschner, Abby, Kohan, Lynn , Lauritsen, Clinton G. , Miller, Franziska , Monsour, Danny, Nader, Antoun , Ogunlaja, Oyindamola, Silberstein, Stephen D., Souza, Dmitri , Kohan, Lynn R , Nader, Antoun , Schwenk, Eric S , Yuan, Hsiangkuo , Englesakis, Marina , Doshi, Tina L , Barad, Meredith J , Gupta, Himanshu, Kissoon, Narayan , Schuster, Nathaniel M. , Schwenk, Eric S. , Yuan, Hsiangkuo , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | July 2, 2025 | Volume: 51 | Issue: 2 | Pages: 117-131

10.1136/rapm-2025-106718 | PMID 40602807 Get It

Introduction Patients hospitalized for headache treatment pose unique challenges to the healthcare system. Currently, there is a lack of evidence-based guidance on management. This practice advisory aims to fill this critical gap by systematically reviewing the existing literature and providing comprehensive, evidence-based recommendations for managing headache patients during hospitalization. Methods In February 2023, the American Society of Regional Anesthesia and Pain Medicine approved this practice advisory proposal. The steering committee selected committee members based on clinical and research expertise in the field of headache medicine. Nine questions were formulated by the committee, and each question was assigned to a group composed of 3–4 members. A systematic literature search for each question was performed in Medline, Embase, Cochrane Database of Systematic Reviews and Web of Science on June 21, 2023. The results from each search were imported into separate Covidence projects for screening, data extraction, and risk of bias assessment. Additionally, relevant systematic reviews (SR) were screened. Each group submitted a structured narrative review along with statements and recommendations based on the US Preventive Services Task Force (USPSTF) format for grading of evidence. While the USPSTF framework was used, including the language in the recommendations, the formal USPSTF methodology, including the SR with meta-analysis and summary tables with forest plots, was not followed because of low overall evidence quality. The interim draft was shared electronically with each collaborator, who was requested to vote anonymously using two rounds of the modified Delphi approach. A consensus recommendation required >75% agreement. Results The panel generated 12 statements and 17 recommendations, along with their strength and certainty of evidence. Following two rounds of Delphi voting, a high consensus was achieved for all statements and recommendations. Most statements received a low-to-moderate level of certainty, and all but one recommendation received grade B or C, which was consistent with the lack of randomized controlled trials supporting most of the drugs in this document. Conclusions This evidence-based practice advisory provides a foundational step toward standardizing inpatient headache care and highlights existing gaps in the literature that should be addressed through rigorous prospective randomized studies.
Design, Development, Funding, and Implementation of the CSRS Registry
Witham, Julie M., Sasso, Rick C., Mummaneni, Praveen V., Riew, K. Daniel , Sardar, Zeeshan M. , Ray, Wilson Z. , Harrop, James S., Protopsaltis, Themistocles S. , Nassr, Ahmad, Vedentam, Aditya, Rhee, John M. , Lawrence, Brandon D. , Ludwig, Steven C. , Ghogawala, Zoher , Mummaneni, Praveen V. , Riew, Kiehyun Daniel , Cho, Samuel K. , Mesfin, Addisu

Mayo Clinic

Clinical Spine Surgery | July 2, 2025 | Volume: 39 | Issue: 3 | Pages: E153-E160

10.1097/bsd.0000000000001833 | PMID 40600728 Get It

Study Design: A national prospective cervical spine surgery registry was developed to archive radiographic studies, patient-reported outcome measures (PROMs), and surgical implant data to assess long-term safety. Objective: To describe the design, development, funding, and implementation of a cervical spine data registry for 1000 patients with myelopathy and radiculopathy. Summary of Background Data: While surgery for cervical radiculopathy and myelopathy is safe and effective, there is significant practice variation among spine surgeons. While randomized clinical trials (RCTs) can provide high-quality comparative effectiveness data, RCTs lack the ability to evaluate the safety and effectiveness of various surgical procedures and implants among heterogenous real-world patient populations. The CSRS Registry was designed to collect patient demographics, outcomes, radiographic imaging, surgical approach, and implant data for the purpose of conducting high-quality research. Methods: Patients with cervical myelopathy or radiculopathy were enrolled in the CSRS National Registry. De-identified patient data, validated PROMs, radiographic data, and implant data were collected from multiple clinical sites across the United States. Results: One thousand patients [mean age, 58 y; 456 (46%) women] were enrolled, with 31% follow-up at 1 year. Five hundred ninety-two patients were diagnosed with radiculopathy, 252 with myelopathy, and 156 with radiculopathy and myelopathy. Patients had significant improvements in their PROMs after surgery. At 1 year, the mean NDI score improved from 37.2 to 20.9 ( P <0.001). The mean self-reported P-mJOA score at baseline was 14.2 and improved to 15.2 by 1 year ( P <0.001). Baseline CSDI score was 23.6 and improved with a 1-year decrease to an average score of 13.6 ( P <0.001). There was significant improvement in PROMIS-10 Physical Health score from 41.0 to 45.9 (n=311; P <0.001) at 1-year follow-up. Conclusions: The CSRS Registry has successfully collected clinical outcomes data that is being leveraged for comparative effectiveness research and evaluations of the long-term safety and effectiveness of spinal implants.
COVID-19 and Cognitive Change in a Community-Based Cohort
Pike, James Russell , Sun, Yifei , Wu, Christina , Suchy‐Dicey, Astrid M. , Elkind, Mitchell S.V., Kucharska‐Newton, Anna , Levine, Deb, Lutsey, Pamela L. , Mosley, Thomas H. , Palta, Priya, Coresh, Josef, Oelsner, Elizabeth C. , Lutsey, Pamela L , Pike, James R , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Demmer, Ryan T. , Cornelius, Talea M. , Kraal, A. Zarina , Balte, Pallavi , Wu, Chaoqi, Allen, Norrina B. , Cushman, Mary , Howard, Virginia J. , Manly, Jennifer J. , Power, Melinda C. , Seshadri, Sudha , Tracy, Russell P. , Walker, Keenan A.

Mayo Clinic

JAMA Network Open | June 30, 2025 | Volume: 8 | Issue: 6 | Pages: e2518648

10.1001/jamanetworkopen.2025.18648 | PMID 40587126 Get It

Importance SARS-CoV-2 infection has been linked to neurotoxic effects and cognitive deficits. Objective To determine whether decreases in cognitive function were accelerated after SARS-CoV-2 infection compared with individuals not infected. Design, Setting, and Participants Multicenter, prospective cohort study from 2016 to 2022 among 3525 participants alive on March 1, 2020, and enrolled in The Atherosclerosis Risk in Communities (ARIC) study and the Collaborative Cohort of Cohorts for COVID-19 Research study who completed a prepandemic cognitive assessment and a pandemic-era assessment of SARS-CoV-2 infection. Final analyses performed in November 2024. Exposure SARS-CoV-2 infection determined via self-report of a positive SARS-CoV-2 test or health care professional diagnosis of COVID-19, a positive SARS-CoV-2 antinucleocapsid antibody response, or presence of an administrative code for COVID-19 on medical records. Main outcomes and measures A neuropsychological battery assessed multiple cognitive domains, and a cocalibrated confirmatory factor analysis generated factor scores for global cognitive function. The primary outcome was the rate of excess change in cognitive function. Results The 3525 eligible participants had a mean (SD) age of 80.8 (4.7) years, 2085 (59.1%) were female, 752 (21.4%) were Black, and 2773 (78.6%) were White. SARS-CoV-2 infection was detected among 307 participants (8.7%), 103 of whom (33.6%) were hospitalized. Among uninfected participants, the mean annualized change in cognitive function was −0.09 (95% CI, −0.13 to −0.04). Compared with this rate, change was faster (β = −0.06; 95% CI, −0.09 to −0.02) among participants hospitalized for infection, but not different from participants who were infected but not hospitalized (β = 0.00; 95% CI, −0.02 to 0.03). The association among participants hospitalized for infection was evident in the cognitive domains of memory and executive function, but not language. Conclusions and relevance This cohort study of older participants found accelerated decreases in cognition among individuals hospitalized for SARS-CoV-2 infection, but not nonhospitalized infection, in comparison with individuals not yet infected.
Predictors of treatment response and overall survival in patients with breast cancer brain metastases treated with stereotactic radiosurgery: a prospective study using the NeuroPoint Alliance SRS Registry
D’Ambrosio, Anthony, Cobb, William S., Grills, Inga S., McInerney, James , Jensen, Randy L. , Chang, Eric L. , Timmerman, Robert , Attia, Albert, Spalding, Aaron C., Walter, Kevin A. , Bydon, Mohamad , Asher, Anthony L. , Sheehan, Jason P. , Katsos, Konstantinos, Katsos, Konstantinos, Michalopoulos, Giorgos D. , Cobb, William S., Andrews, David William , Pouratian, Nader

Mayo Clinic

Journal of Neurosurgery | June 27, 2025 | Volume: 143 | Issue: 5 | Pages: 1419-1430

10.3171/2025.3.jns241471 | PMID 40577855 Get It

OBJECTIVE The aim of this study was to evaluate mortality and progression outcomes in patients undergoing stereotactic radiosurgery (SRS) for breast cancer brain metastases and to identify associated risk factors using a national quality registry. METHODS The NeuroPoint Alliance (NPA) SRS Registry was employed for this study, which conducted prospective enrollment of patients undergoing SRS at 16 participating centers from 2017 to 2024. Outcomes of interest included the post-SRS EQ-5D score change, overall survival, local progression, out-of-field progression, and overall intracranial progression. For all time-to-event analyses, Kaplan-Meier curves and multivariable Cox regressions with hazard ratios were used. RESULTS A total of 138 patients (127 female, mean age 59.8 years) were identified; 46.4% had a single lesion, 42.0% had 2–4 lesions, and 11.6% had ≥ 5 lesions, while 87.0% had a Karnofsky Performance Status (KPS) score between 80 and 100. The median overall survival was 17.9 months, and independent predictors of all-cause mortality included a KPS score ≤ 90 (HR 6.73) and diabetes mellitus (HR 3.35). The median time to local progression was 19.8 months. More than 5 lesions at baseline (HR 9.03) and a marginal dose ≤ 17.6 Gy (HR 8.00) were predictive of local recurrence. The median was not reached for out-of-field progression, and predictors included ≥ 2 lesions at the time of SRS (HR 3.20) and a marginal dose ≤ 17.6 Gy (HR 4.61). At the final follow-up assessment, 17.1% of patients experienced no change according to the EQ-5D, while 34.3% had improvement, 11.4% had mixed results, and 37.1% had worsened health. In the multivariable linear regression model, pre-SRS resection (r = 1.92) and baseline EQ-5D score (r = 1.29) were statistically significant predictors of quality of life at the final follow-up assessment. CONCLUSIONS Using real-world data from the NPA SRS Registry, this study demonstrated comparable outcomes in patients who underwent SRS for breast cancer brain metastases compared with those of previous literature. The number of lesions at the time of SRS and the marginal dose were independent risk factors for local recurrence, out-of-field progression, and overall intracranial progression. Pre-SRS resection and baseline EQ-5D score were independent predictors of quality of life following SRS.